Tests a patient care pathway for complications in people with multiple myeloma
Tests a care pathway for complications in adults with multiple myeloma after stem cell transplant.
Plain-language title generated from the registry record
Registry title: PASCA-MM Study. Impact of the PASCA (PArcours de Santé au Cours du CAncer) Program on Complications Associated With Multiple Myeloma and/or Its Treatments in the Context of a First Hematopoietic Stem Cell Autograft, in Adults Aged 18 to 70.
Key facts
- Where
- Épagny, Grenoble, Lyon, Montpellier, Saint-Etienne, and Villefranche-sur-Saône, FranceSee the 6 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT05947136, who can take part
Where in France
- CH Annecy GenevoisÉpagny, FranceTaking people
- CHU La TroncheGrenoble, FranceTaking people
- Centre Leon BerardLyon, FranceTaking people
- Centre Hospitalier Universitaire de MontpellierMontpellier, FranceTaking people
- CHU de St EtienneSaint-Etienne, FranceTaking people
- Le Centre Hôpitaux Nord-Ouest Villefranche-sur-SaôneVillefranche-sur-Saône, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Leon Berard
- Trial code
- NCT05947136
- Record updated
- 11 June 2026
- Original description
This is a prospective, multicentre, phase III, randomised, controlled intervention study.Read full original descriptionShow less
PASCA-MM Study. Impact of the PASCA (PArcours de Santé au Cours du CAncer) Program on Complications Associated With Multiple Myeloma and/or Its Treatments in the Context of a First Hematopoietic Stem Cell Autograft, in Adults Aged 18 to 70.
This is a prospective, multicentre, phase III, randomised, controlled intervention study.
Two groups of patients with equal numbers will be studied and each patient will be allocated to one of the two groups described below by randomisation (ratio 1:1).
Each patient will be allocated to one of the two groups described below by randomisation (ratio 1:1).
- PASCA interventional group
For both the 7 complications of interest (primary objective) and the 13 secondary complications (secondary objective), a specific and proactive referral will be made systematically after each screening assessment, depending on the level of risk, estimated according to decision trees (management guide) and through the dedicated PASCA network of healthcare professionals, in order to initiate early treatment and follow-up if necessary.
- Control group
For the 7 complications of interest (primary objective) as well as for the 13 complications (secondary objective): all the data from each identification check-up will be sent to the onco-haematological transmitted to the referring onco-haematologists, so that they can initiate their own management.
=> For all patients, regardless of group
All patients will receive four screening assessments covering the 7 complications of interest and 13 secondary complications:
* Visit No.1 (T1), 1-2 months after the autologous haematopoietic stem cell transplantation (aHSCT), corresponding to the patient's visit to his or her Multiple Myeloma (MM) monitoring consultation and/or the start of his or her consolidation treatment. * Visit No.2 (T2), 4 months after aHSCT, corresponding to a patient's visit for the end of consolidation treatment; * Visit No.3 (T3), 14 months after the last aHSCT, corresponding to a visit by the patient during his or her maintenance treatment; * Visit No.4 (T4), 24 months after the last aHSCT, corresponding to a visit by the patient for a MM monitoring consultation.
Inclusion: Age ≥ 18 years old and ≤ 70 years old; Patient treated in an investigation center; Symptomatic multiple myeloma eligible for autologous hematopoietic stem cell transplantation (HSCT); In complete response, complete response, very good complete response, or partial before HSCT; First induction-type treatment (Isa-KRD/dara-VRD/dara-VTD/VRD/VTD/dara-VRD), intensification therapy with melphalan, HSCT, consolidation, maintenance including at least one drug immunomodulator; ECOG performance status WHO ≤ 2; No history or coexistence of other primary cancer apart from basal cell cancer cutaneous; Able to understand, read and write French; Having signed and dated the informed consent.
Exclusion: Unable to be monitored for medical, social, family, geographical or psychological, throughout the duration of the study; Deprived of liberty by court or administrative decision; Not affiliated with a health insurance plan; Not having declared an attending physician; Not domiciled in the Auvergne-Rhône-Alpes region or in the Saône-et-Loire department; Not available and/or not willing to participate in the project for the entire duration of the study; Pregnant women, breastfeeding women, people in emergency situations, people incapable of personally giving their consent including adults under guardianship.